These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7557895)

  • 1. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
    Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
    Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.
    Flavell DJ; Cooper S; Morland B; French R; Flavell SU
    Br J Cancer; 1992 Apr; 65(4):545-51. PubMed ID: 1373293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
    Flavell DJ; Cooper S; Morland B; Flavell SU
    Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
    Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
    Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
    Flavell DJ; Boehm DA; Noss A; Flavell SU
    Br J Cancer; 1997; 75(7):1035-43. PubMed ID: 9083340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
    Flavell DJ; Warnes S; Noss A; Flavell SU
    Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
    French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
    Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
    Morland BJ; Barley J; Boehm D; Flavell SU; Ghaleb N; Kohler JA; Okayama K; Wilkins B; Flavell DJ
    Br J Cancer; 1994 Feb; 69(2):279-85. PubMed ID: 7507691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
    Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
    French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ
    Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
    Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
    Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
    Flavell DJ; Noss A; Pulford KA; Ling N; Flavell SU
    Cancer Res; 1997 Nov; 57(21):4824-9. PubMed ID: 9354445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.
    French RR; Bell AJ; Hamblin TJ; Tutt AL; Glennie MJ
    Leuk Res; 1996 Jul; 20(7):607-17. PubMed ID: 8795695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
    Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
    Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
    Bergamaschi G; Perfetti V; Tonon L; Novella A; Lucotti C; Danova M; Glennie MJ; Merlini G; Cazzola M
    Br J Haematol; 1996 Jun; 93(4):789-94. PubMed ID: 8703804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
    Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT
    J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.